Car-T on Bioeconhttps://en.bioecon.ru/technologies/car-t/Recent content in Car-T on BioeconHugoen-USSat, 11 Jul 2026 11:33:52 +0700CAR-T cell therapyhttps://en.bioecon.ru/technology/car-t-cell-therapy/Sat, 11 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/car-t-cell-therapy/A patient’s own T cells are collected, engineered with a chimeric antigen receptor (CAR) using a lentiviral vector, expanded and re-infused to kill cancer — an approved one-time living-drug class spanning CD19 lymphoma/leukemia and BCMA multiple myeloma, now advancing toward off-the-shelf allogeneic products.